(19)

(11)

EP 3 829 536 A1

(12)

(43) Date of publication: 09.06.2021 Bulletin 2021/23 (21) Application number: 19768952.4 (22) Date of filing: 29.08.2019

(51) International Patent Classification (IPC):  A61K 9/00(2006.01) A61P 23/02(2006.01) A61F 13/00(2006.01) A61L 15/44(2006.01) A61L 24/00(2006.01) A61L 15/00(2006.01) A61K 9/70(2006.01) (86) International application number: PCT/US2019/048846 (87) International publication number: WO 2020/047277 (05.03.2020 Gazette 2020/10)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 31.08.2018 US 201862725694 P (71) Applicant: Rilento Pharma LLC Raleigh, NC 27615 (US)

(72) Inventors: NESHAT, Kevin Raleigh, North Carolina 27615 (US) DAUNCH, William Andrew Cary, North Carolina 27519 (US) PARKER, Anthony A. Newtown, Pennsylvania 18940 (US) HANNA, Mark Franklin Raleigh, North Carolina 27614 (US) DIONNE, Dr. Raymond A. New Bern, North Carolina 28560 (US) (74) Representative: Isarpatent  Patent- und Rechtsanwälte Behnisch Barth Charles Hassa Peckmann & Partner mbB Friedrichstrasse 31 80801 München 80801 München (DE)